Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Reddit Slides 5% Before Earnings as U.S. User Growth Worries Mount; Snap Sinks 4%, Pinterest Drops 2%,... (24/7 Wall St.) +++ PINTEREST Aktie -3,26%

PFIZER Aktie

 >PFIZER Aktienkurs 
26.575 EUR    +0.2%    (TradegateBSX)
Ask: 26.595 EUR / 4550 Stück
Bid: 26.57 EUR / 4550 Stück
Tagesumsatz: 63690 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: -2,1%
1 Monat: +4,8%
3 Monate: +19,4%
6 Monate: +17,2%
1 Jahr: +25,8%
laufendes Jahr: +24,5%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Profil:  Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare di..
>Volltext..
Marktkapitalisierung:  150756.57 Mio. EUR
Unternehmenswert:  196193.27 Mio. EUR
Umsatz:  57207.52 Mio. EUR
EBITDA:  21116.02 Mio. EUR
Nettogewinn:  3890.72 Mio. EUR
Gewinn je Aktie:  0.68 EUR
Schulden:  56756.66 Mio. EUR
Liquide Mittel:  876.58 Mio. EUR
Operativer Cashflow:  12036.79 Mio. EUR
Bargeldquote:  0.36
Umsatzwachstum:  2.92%
Gewinnwachstum:  -58.35%
Dividende je Aktie:  1.48 EUR
Dividendenrendite:  5.84%
Dividendenschätzung:  5.87%
Div. Historie:  24.07.26 - 0.378013€
08.05.26 - 0.364726€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  29.10.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5699.67 Mio. St.
Frei handelbar: 99.91%
Rückkaufquote: -
Mitarbeiter: 75000
Umsatz/Mitarb.: 0.75 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -3.14%
Bewertung:
KGV: 40.41
KGV lG: 10.08
KUV: 2.62
KBV: 2.04
PEG-Ratio: -
EV/EBITDA: 9.29
Rentabilität:
Bruttomarge: 64.83%
Gewinnmarge: 6.81%
Operative Marge: 26.57%
Managementeffizenz:
Gesamtkaprendite: 2.13%
Eigenkaprendite: 4.99%
 >PFIZER Anleihen 
>PFIZER Peer Group
 
29.10.26 - 17:01
Looking for income? These dividend stocks have high yields that seem well supported. (MarketWatch)
 
Ford, Pfizer and Verizon are among 11 stocks that passed a screen of the S&P 500 for high dividend yields that are expected to be well covered by the companies' free cash flow....
29.10.26 - 13:54
CopperWood Senior Living to Host Ceremonial Groundbreaking Nov. 4 for Adaptive Reuse of Historic Peapack-Gladstone Corporate Campus (PR Newswire)
 
Bob Hillier-designed Pfizer/Beneficial Finance campus, nominated to the National Register of Historic Places, becomes luxury senior living PEAPACK, N.J., Oct. 29, 2026 /PRNewswire/ -- Distinctive Living and development partners Melillo Equities and PointsFive will host a ceremonial......
29.10.26 - 13:06
Metaphore Biotechnologies Appoints Frank D′Amelio and Pascal Deschatelets to Board of Directors (Business Wire)
 
D'Amelio has built and reshaped businesses across technology and pharmaceuticals, including nearly 15 years helping lead Pfizer's financial and operational transformationAs a serial entrepreneur and inventor, Deschatelets applies scientific rigor to building companies around new ways to intervene in disease, with a record of advancing first-in-class medicinesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Metaphore Biotechnologies (“Metaphore”), a Flagship Pioneering company developing antibody medicines designed for the dynamic biology of complex disease, today announced the appointment of Frank D'Amelio and Pascal Deschatelets, Ph.D., as independent directors to the Company's Board. As Metaphore prepares for clinical development, their appointments bring substantial scientific and business leadership to translating the Company's platform into new categories of antibody medicines designed to activate targets, tune signaling, or engage multiple targets.“Frank brings financial judgment tested through major t...
29.10.26 - 10:30
Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer′s Q3 Fate on Nov. 3 (24/7 Wall St.)
 
Pfizer (NYSE:PFE) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date. This report tests whether non-COVID growth and obesity progress can keep outpacing a shrinking pandemic franchise. Strong Beats Mask a Shrinking COVID Base Last quarter, adjusted EPS of $0.77 exceeded the $0.6822 consensus, and revenue of […]...
29.10.26 - 08:48
10.000 Euro investieren? 2 krisenfeste Aktien für 500 Euro Dividende! (Aktienwelt360)
 
Pfizer und Allianz versprechen attraktive Dividenden. Doch wie realistisch sind 500 Euro jährlich mit 10.000 Euro Einsatz – und welche Risiken lauern? Der Artikel 10.000 Euro investieren? 2 krisenfeste Aktien für 500 Euro Dividende! ist zuerst erschienen auf Aktienwelt360....
29.10.26 - 00:00
Pfizer (PFE) Stock Sinks As Market Gains: Here′s Why (Zacks)
 
Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day....
28.10.26 - 18:00
Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy? (Zacks)
 
Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges....
28.10.26 - 15:03
ManpowerGroup Elects Lidia Fonseca to its Board of Directors (PR Newswire)
 
MILWAUKEE, Oct. 28, 2026 /PRNewswire/ -- ManpowerGroup (NYSE: MAN) today announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer, to its Board of Directors, effective November 1, 2026. "Lidia brings a rare combination of......
27.10.26 - 14:24
Pfizer′s ELREXFIO Succeeds In Phase 3 Trial For Multiple Myeloma (AFX)
 
NEW YORK CITY (dpa-AFX) - On Tuesday, Pfizer's ELREXFIO (elranatamab) met the primary endpoint of progression-free survival (PFS) in the Phase 3 MagnetisMM-32 trial, reducing the risk of disease p......
27.10.26 - 12:30
Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.10.26 - 12:06
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors (Business Wire)
 
Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led multiple registration programs through regulatory approvalAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymeworks (Nasdaq: ZYME). Dr. Schayowitz has nearly 20 years of experience in oncology drug development and has led dozens of global development programs, including multiple registration programs that resulted in regulatory approvals. He previously served as an Operating Partner at EcoR1 Capital. Before that, he held roles of increasing responsibility at Pfizer Oncology, including...
27.10.26 - 06:54
Pfizer′s Talzenna-Xtandi Gets Expanded FDA Approval For Earlier Prostate Cancer Treatment (AFX)
 
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) on Monday announced that the U.S. FDA expanded approval of Talzenna plus Xtandi in the treatment of men with metastatic androgen pathway modulation-naïv......
26.10.26 - 23:12
Pfizer Talzenna/Xtandi combo approved for earlier prostate cancer setting (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.10.26 - 14:18
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady (24/7 Wall St.)
 
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA) stock is down 7% to $185.74 in morning trading, a move that reprices the commercial upside of its flagship cancer program. That decline extends a […]...
26.10.26 - 09:00
Pfizer Buy (DPA-AFX)
 
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer mit einem Kursziel von 36 US-Dollar auf "Buy" belassen. Akash Tewari bezieht sich in seiner am Montag vorliegenden Einschätzung zu Phase-II-Daten der Studie FOURLIGHT-1 ......
25.10.26 - 22:48
Bill Gates Faces Court Over Claims COVID Jabs Were ′Lethal Biological Weapons′ (ZeroHedge)
 
Bill Gates Faces Court Over Claims COVID Jabs Were 'Lethal Biological Weapons' Authored by Steve Watson via Modernity, In a packed courtroom in Leeuwarden, the official COVID story is being put on trial as Dutch plaintiffs demand personal liability from Bill Gates, Pfizer CEO Albert Bourla, former Prime Minister Mark Rutte and others for what their lawyer calls a coordinated global deception. The civil case, filed in 2023, alleges the mRNA injections functioned as lethal biological weapons rolled out through unlawful public deception tied to the World Economic Forum's Great Reset. Two of the original seven plaintiffs have already died. Defendants' lawyers rejected every claim, repeating that the shots were safe and effective and developed through normal science. ?BILL GATES/BOURLA TRIAL: "These injections are a BIOLOGICAL WEAPON." "COVID-19 injections are LETHAL." "The global deployment of this biological weapon can only take place through the UNLAWFUL deception of...
25.10.26 - 16:03
Appeals Court Throws Out Alex Berenson′s Case Against Pfizer Executives (ZeroHedge)
 
Appeals Court Throws Out Alex Berenson's Case Against Pfizer Executives Authored by Zachary Stieber via The Epoch Times, A federal appeals court has thrown out a lawsuit from independent journalist Alex Berenson accusing Pfizer executives of pressuring Twitter to censor him because of his comments opposing COVID-19 vaccines. In a file image from video, Alex Berenson speaks during an interview with The Epoch Times. The Epoch TimesA unanimous panel of U.S. Court of Appeals for the Second Circuit judges on Oct. 20 determined that Twitter's terms of service were not altered by a subsequent "five strikes" policy and promises made to Berenson that his posts on COVID-19 vaccines would not lead to strikes. The terms said that Twitter may suspend or terminate an account "at any time for any or no reason," including for violations of Twitter rules and policies. "The five-strike policy is clearly among the 'Rules and Policies' that the Terms of Service contemplates," the circuit judges said in the de...
24.10.26 - 19:45
Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.10.26 - 15:18
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip (24/7 Wall St.)
 
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) came back positive, yet the selling hasn't stopped. Those numbers landed short of the loftiest hopes built into a long rally. Moderna stock is down 4% to $193.62 in morning trading. The move extends an 18% plunge from the prior session […]...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wann wird der Zankapfel endlich zur verbotenen Frucht erklärt. - Wieslaw Brudzinski
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!